NOVOLIN N
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOVOLIN N (NOVOLIN N).
Insulin analog that lowers blood glucose by promoting cellular uptake of glucose, inhibiting hepatic glucose production, and stimulating lipogenesis and protein synthesis.
| Metabolism | Metabolized by insulin-degrading enzyme (IDE) primarily in the liver and kidneys. |
| Excretion | Renal: 30-80% of dose excreted as unchanged insulin and metabolites. Biliary/fecal: negligible (<1%). |
| Half-life | 10-12 hours for intermediate-acting insulin, with a peak effect at 2-8 hours and duration up to 24 hours. Terminal half-life in subcutaneous depot is 4-6 hours. |
| Protein binding | ~55% bound to albumin and beta-globulins. |
| Volume of Distribution | 0.1-0.2 L/kg, approximating extracellular fluid volume, indicating limited extravascular distribution. |
| Bioavailability | Subcutaneous: 55-80% due to enzymatic degradation at injection site. Intravenous: 100%. |
| Onset of Action | Subcutaneous: 1-2 hours. |
| Duration of Action | Subcutaneous: 18-24 hours, with peak effect at 4-12 hours. Duration is longer with higher doses. |
| Molecular Weight | 5808 |
Subcutaneous injection. Typical starting dose for type 1 diabetes: 0.5-1.0 units/kg/day divided into 2 doses (morning and evening). For type 2 diabetes: 10 units once or twice daily, adjusted based on blood glucose levels.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for renal impairment; monitor glucose closely. |
| Liver impairment | No specific dose adjustment required for hepatic impairment; monitor glucose closely. |
| Pediatric use | Individualized based on blood glucose goals. Typical starting dose: 0.25-0.5 units/kg/day subcutaneously in 2 divided doses. |
| Geriatric use | Start with lower doses (e.g., 0.25-0.5 units/kg/day) and titrate slowly to avoid hypoglycemia; monitor renal function. |
| 1st trimester | Insulin is the preferred agent for glycemic control in pregnancy. No known teratogenic risk; however, hypoglycemia may occur. Dose adjustments are often necessary due to changing insulin sensitivity. |
| 2nd trimester | Insulin requirements typically increase during the second trimester due to placental hormone production. Monitor glucose closely and adjust doses accordingly. Hypoglycemia risk remains. |
| 3rd trimester | Insulin requirements often continue to rise in the third trimester. Postpartum, requirements drop sharply. Hypoglycemia is a concern; careful monitoring is essential. |
Clinical note
Comprehensive clinical and safety monograph for NOVOLIN N (NOVOLIN N).
| Placental transfer | Insulin does not cross the placental barrier in significant amounts due to its large molecular weight; however, antibody-bound insulin may cross to a limited extent. |
| Breastfeeding | Insulin is excreted into breast milk in minimal amounts and is not expected to cause adverse effects in the breastfed infant. However, the drug may affect maternal milk production if used shortly after delivery. |
■ FDA Black Box Warning
Never share a NOVOLIN N FlexPen, PenFill cartridge, or vial between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
| Serious Effects |
Hypersensitivity to human insulin or any excipientsHypoglycemia
| Precautions | Hypoglycemia: Can occur with insulin therapy; monitor blood glucose levels., Hypokalemia: May cause hypokalemia; monitor potassium levels in patients at risk., Fluid retention and heart failure: Can occur, especially when used with thiazolidinediones (TZDs)., Allergic reactions: Local or systemic allergic reactions may occur., Needle sharing: Risk of blood-borne pathogen transmission; do not share pens or syringes. |
| Food/Dietary | No specific food interactions expected with NPH insulin. However, patients should maintain consistent carbohydrate intake timing and amount relative to insulin dose to prevent hypoglycemia or hyperglycemia. Alcohol consumption may increase the risk of hypoglycemia, especially if consumed on an empty stomach or with exercise. Grapefruit is not known to interact with insulin. |
Loading safety data…
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Insulin is not teratogenic. Poor glycemic control increases risks of congenital anomalies (first trimester), macrosomia, neonatal hypoglycemia (third trimester). |
| Fetal Monitoring | Monitor blood glucose, HbA1c, fetal growth ultrasound, amniotic fluid index, fetal heart rate monitoring in third trimester. |
| Fertility Effects | No direct effects on fertility. Glycemic control improves fertility outcomes. |
| Clinical Pearls | NOVOLIN N (NPH insulin) is an intermediate-acting insulin with onset of action in 2-4 hours, peak at 4-12 hours, and duration up to 18-24 hours. It should be resuspended by rolling the vial or pen gently at least 10 times until a uniform milky white suspension appears before each use. Administer subcutaneously, typically before breakfast and/or before dinner. Because of its peak activity, patients are at higher risk for hypoglycemia during the late morning (if AM dose) or during the night (if PM dose). Adjust doses based on blood glucose trends, especially fasting and pre-meal values. Be aware that NPH insulin has a variable absorption profile; consider switching to insulin analogs if hypoglycemia or glycemic variability is problematic. Do not use in insulin pumps or intravenous administration. |
| Patient Advice | Roll the vial or pen gently between your palms at least 10 times before each use to resuspend the insulin; do not shake vigorously. · Inject the insulin subcutaneously into the abdomen, thigh, or upper arm; rotate injection sites to prevent lipodystrophy. · Monitor your blood glucose regularly, especially before meals and at bedtime, and be aware that NPH insulin peaks 4-12 hours after injection, which increases hypoglycemia risk. · Recognize symptoms of hypoglycemia (e.g., sweating, tremor, confusion) and treat immediately with fast-acting sugar like juice or glucose tablets. · Store unopened vials/pens in the refrigerator; once opened, keep at room temperature and discard after 28 days. · Do not skip meals and maintain consistent carbohydrate intake to avoid blood glucose swings. · Carry a source of sugar and medical identification indicating diabetes and insulin use. |